PubRank

T Lock

Author PubWeight™ 11.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995 1.81
2 Mammalian meiotic telomeres: protein composition and redistribution in relation to nuclear pores. Mol Biol Cell 2000 1.39
3 Outcomes following repair of quadriceps tendon ruptures. J Orthop Trauma 1998 1.10
4 Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the "invisible" lesion load. Magn Reson Imaging 1994 1.09
5 Total and partial ovariohysterectomy in seven mares. Equine Vet J 2004 1.06
6 The use of cold therapy after anterior cruciate ligament reconstruction. A prospective, randomized study and literature review. Am J Sports Med 1997 0.93
7 Molecular cloning and expression of a cDNA for human kidney cysteine conjugate beta-lyase. FEBS Lett 1995 0.86
8 Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine. Psychopharmacology (Berl) 1994 0.79
9 Predictors of response to amine-specific antidepressants. J Affect Disord 1995 0.77
10 Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant. Br J Pharmacol 2009 0.76
11 A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness. J Psychopharmacol 1994 0.75
12 Neuraminidase-augmented anticarcinoembryonic antigen (CEA)-complement lysis of human colon tumor cells: lack of correlation with anti-CEA-mediated K-cell lysis and iodine-125 binding. J Natl Cancer Inst 1979 0.75
13 Molecular cloning and expression of cDNAs for rat and human kidney cysteine conjugate beta-lyase. Biochem Soc Trans 1996 0.75
14 Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Int Clin Psychopharmacol 1993 0.75
15 Sudden cardiac death and antidepressants. Br J Psychiatry 1991 0.75
16 Developments in inhaled immunosuppressive therapy for the prevention of pulmonary graft rejection. BioDrugs 1998 0.75